OraSure Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:12 pm EST
Share
OraSure Technologies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 89.19 million compared to USD 116.46 million a year ago. Net income was USD 11.16 million compared to USD 5.6 million a year ago. Basic earnings per share from continuing operations was USD 0.15 compared to USD 0.08 a year ago. Diluted earnings per share from continuing operations was USD 0.15 compared to USD 0.08 a year ago.
For the nine months, sales was USD 329.59 million compared to USD 264.4 million a year ago. Net income was USD 33.58 million compared to net loss of USD 32.93 million a year ago. Basic earnings per share from continuing operations was USD 0.46 compared to basic loss per share from continuing operations of USD 0.45 a year ago. Diluted earnings per share from continuing operations was USD 0.45 compared to diluted loss per share from continuing operations of USD 0.45 a year ago.
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.